Key Insights

Highlights

Treatment Research

1 treatments under study, led by Removal Or Leaving Of Laa Occluders

Research Leaders

20 sponsors active, led by Jesper van der Pals, Lund University Hospital, Lund, Sweden.

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

Trial Status

Unknown1

Clinical Trials (1)

Showing 1 of 1 trials
NCT05014477Unknown

Therapy Strategies After LAA Occluder Device Embolization

Showing all 1 trials

Research Network

Common Treatments

  • Removal Or Leaving Of Laa Occluders1

Active Sponsors

  • Jesper van der Pals, Lund University Hospital, Lund, Sweden.1
  • Juan Fernández-Armenta, Hospital Universitario Puerta del Mar, Cádiz, Spain1
  • Ignacio Cruz Gonzalez, University Hospital of Salamanca, Castillay Leon, Spain1
  • Jung-Sun Kim, Yonsei University Hospital, Seoul, South Korea1
  • Giacomo Boccuzzi, Ospedale san Giovanni Bosco, Torino, Italy1

Top Investigators

  • Sophie Eppinger1

    CardioVascular Center (CVC) Frankfurt, Seckbacher Landstraße 65, 60389 Frankfurt am Main, Hesse, Germany

Related Conditions

  • Left Atrial Appendage Occluder1
  • Device Embolisation1
  • Risk Factors1

Activity Timeline